The project “New method for reducing toxicity of methotrexate after high-dose chemotherapy in oncological children by hemoperfusion using HA230,330 absorbers” won a grant for financing scientific and (or) scientific and technical projects | Корпоративный фонд "University Medical Center"

The project “New method for reducing toxicity of methotrexate after high-dose chemotherapy in oncological children by hemoperfusion using HA230,330 absorbers” of the doctors of the Clinical  Academic Department of Anesthesia and Intensive Care, the Unit of Pediatric Anesthesiology, Reanimation and Intensive Care with an operating unit (Head of the unit Saparov A.I., Tobylbaeva Z.S., Sazonov V.G., dialysis doctor Isakov S.E., Mironova O.A., Kamataeva G.T., Kakenov E.K., Muratbekova B.M., Zhusipov B.P.) won a grant for financing scientific and (or) scientific and technical projects for 2021-2023 from the Ministry of Education and Science of the Republic of Kazakhstan.

According to the project leaders, this study will reduce the toxic effect of methotrexate in the blood and improve the survival rate of patients with cancer.

This project contains an innovative goal and new developments that allow to expand the range of knowledge and practice in the field of extracorporeal blood purification in children after complicated chemotherapy due to an increased concentration of methotrexate.

For the first time in the world, the substantiation of the scientific idea and the detailing of the complex treatment of complications by hemoperfusion with the help of HA 230.330 absorbers will be presented.          Note that the project was highly appreciated by experts at 43.18 points and ranks 13th in the list of more than 150 participants. The research results will be reflected in COXON publications, peer-reviewed foreign editions, conference proceedings.